Gastroenterologie up2date, Table of Contents Gastroenterologie up2date 2024; 20(01): 12-13DOI: 10.1055/a-2207-8578 Wichtige Studien im Fokus Kommentar zu: Divarasib und Adagrasib: sicher und wirksam bei KRAS-G12C-positiven Tumoren? Christoph Roderburg , Catherine Leyh , Tom Lüdde Recommend Article Abstract Buy Article All articles of this category Comment on: Divarasib und Adagrasib: sicher und wirksam bei KRAS-G12C-positiven Tumoren?Gastroenterologie up2date 2024; 20(01): 10-10DOI: 10.1055/a-2207-5470 Full Text References Literatur 1 Kim D Xue JY, Lito P. Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients. Cell 2020; 183: 850-859 2 Skoulidis F, Li BT, Dy GK. et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N Engl J Med 2021; 384: 2371-2381 3 Jänne PA, Riely GJ, Gadgeel SM. et al. Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation. N Engl J Med 2022; 387: 120-131 4 Yaeger R, Weiss J, Pelster MS. Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C. N Engl J Med 2023; 388: 44-54 5 Bekaii-Saab TS, Yaeger R, Soira AI. Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation. J Clin Oncol 2023; 41: 4097-4106 6 Purkey H. Abstract ND11: Discovery of GDC-6036, a clinical stage treatment for KRAS G12C-positive cancers. Cancer Res 2022; 82 (Suppl. 12) ND11 7 Fakih MG, Salvatore L, Esaki T. et al. Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C. N Engl J Med 2023; 389: 2125-2139
